VYGR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -36.72% compared to Voyager Therapeutics's net margin of -49.65%. Voyager Therapeutics's return on equity of 9.12% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Voyager Therapeutics has a consensus price target of --, signalling upside risk potential of 195.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Voyager Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Voyager Therapeutics.

Voyager Therapeutics has a beta of 0.896, which suggesting that the stock is 10.374% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Voyager Therapeutics's net income of -$9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.89x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.97x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -36.72% compared to Voyager Therapeutics's net margin of -2357.27%. Voyager Therapeutics's return on equity of 9.12% beat Palatin Technologies's return on equity of --.

Voyager Therapeutics has a consensus price target of --, signalling upside risk potential of 195.85%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Voyager Therapeutics, analysts believe Palatin Technologies is more attractive than Voyager Therapeutics.

Voyager Therapeutics has a beta of 0.896, which suggesting that the stock is 10.374% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are larger than Palatin Technologies quarterly revenues of $350K. Voyager Therapeutics's net income of -$9M is lower than Palatin Technologies's net income of -$7.8M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.89x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.97x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -36.72% compared to Voyager Therapeutics's net margin of -131.25%. Voyager Therapeutics's return on equity of 9.12% beat Rhythm Pharmaceuticals's return on equity of -208.96%.

Voyager Therapeutics has a consensus price target of --, signalling upside risk potential of 195.85%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $72.82 which suggests that it could grow by 30.38%. Given that Voyager Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Voyager Therapeutics is more attractive than Rhythm Pharmaceuticals.

Voyager Therapeutics has a beta of 0.896, which suggesting that the stock is 10.374% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.141, suggesting its more volatile than the S&P 500 by 114.099%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are smaller than Rhythm Pharmaceuticals quarterly revenues of $33.3M. Voyager Therapeutics's net income of -$9M is higher than Rhythm Pharmaceuticals's net income of -$43.6M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.89x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.97x versus 29.98x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -36.72% compared to Voyager Therapeutics's net margin of 7.2%. Voyager Therapeutics's return on equity of 9.12% beat Sarepta Therapeutics's return on equity of 12.48%.

Voyager Therapeutics has a consensus price target of --, signalling upside risk potential of 195.85%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 51.85%. Given that Voyager Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Voyager Therapeutics is more attractive than Sarepta Therapeutics.

Voyager Therapeutics has a beta of 0.896, which suggesting that the stock is 10.374% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Voyager Therapeutics's net income of -$9M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.89x while Sarepta Therapeutics's PE ratio is 79.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.97x versus 7.48x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.